Oil-Based Adjuvant Formulations for Controlled Antigen Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing adjuvants for vaccines are limited in their ability to effectively enhance immune responses, often causing adverse effects and failing to meet criteria such as slow antigen release, safety, and compatibility across multiple species.
Innovation Solution
Development of novel adjuvant formulations comprising an oily phase with monophosphoryl lipid A or analogs, immunostimulatory oligonucleotides, and other components like sterols and saponins, designed to provide controlled antigen release and enhanced immune stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional adjuvants like Freund's Complete Adjuvant are used to enhance immune response, then the immune response is significantly increased, but severe adverse effects such as uncontrolled inflammation and poor host tolerance occur
Solution Approach 1:
The patent segments the adjuvant system into distinct functional components: an oil phase containing specific adjuvants (alum, calcium phosphate, or calcium carbonate) and an aqueous phase containing antigens and immunostimulants. This segmentation allows each component to perform its specific function while reducing the harmful effects associated with traditional emulsion-based adjuvants like Freund's Complete Adjuvant.
Solution Approach 2:
The patent changes the physical and chemical parameters of the adjuvant system by using solid particulate materials (alum, calcium phosphate, calcium carbonate) instead of liquid oil emulsions. This parameter change from liquid to solid phase eliminates the severe inflammatory responses associated with traditional adjuvants while maintaining immunogenicity enhancement.
2Reliability
If homogeneous preparations or purified protein subunits are used as antigens, then vaccine purity is improved, but the immune response becomes poor
Solution Approach 1:
The patent creates a composite vaccine system combining purified protein subunits or homogeneous antigen preparations with solid particulate adjuvants (alum, calcium phosphate, or calcium carbonate) and immunostimulants. This composite approach maintains the purity benefits of homogeneous preparations while adding the immunogenicity enhancement needed to achieve strong immune responses with smaller antigen doses.
3Ease of manufacture
If synthetic and subunit vaccines are produced, then production cost is reduced and scalability is improved, but adjuvant compatibility and effectiveness become limited
Solution Approach 1:
The patent develops a universal adjuvant platform using solid particulate materials (alum, calcium phosphate, calcium carbonate) that can be effectively combined with various synthetic and subunit vaccines. This multi-functional approach allows the same adjuvant system to enhance different types of purified antigens, making it adaptable to various vaccine formulations and reducing overall production costs.
Data Source
AI summary
The instant invention provides various formulations comprising combinations of immunostimulating oligonucleotides, polycationic carriers, sterols, saponins, quaternary amines, TLR-3 agonists, glycolipids, and MPL-A or analogs thereof in oil emulsions, use thereof in preparations of immunogenic compositions and vaccines, and use thereof in the treatment of animals.